IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v3y2019i3d10.1007_s41669-018-0115-y.html
   My bibliography  Save this article

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma

Author

Listed:
  • Ash Bullement

    (BresMed
    Delta Hat)

  • Paul Nathan

    (Mount Vernon Cancer Centre)

  • Anna Willis

    (BresMed)

  • Amerah Amin

    (Merck Serono)

  • Cameron Lilley

    (BresMed)

  • Ceilidh Stapelkamp

    (Merck Serono)

  • Anthony Hatswell

    (Delta Hat
    University College London)

  • Chris Pescott

    (Merck KGaA)

  • Murtuza Bharmal

    (Merck KGaA)

Abstract

Background Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed treatment options for patients with mMCC, and prognosis was poor. A cost-effectiveness analysis was conducted for avelumab, a newly available treatment option for mMCC, versus standard care (SC), from a UK National Health Service perspective. Methods A partitioned survival model was developed to assess the lifetime costs and effects of avelumab versus SC. Data from the JAVELIN Merkel 200 trial (NCT02155647) were used to inform estimates of quality-adjusted life-years (QALYs). Unit costs and associated frequencies of use were informed by published literature and clinical expert opinion. Results were presented as incremental cost-effectiveness ratios (ICERs, i.e. the cost per QALY gained) for treatment-experienced (TE) and treatment-naïve (TN) patients. Uncertainty was explored through a range of sensitivity analyses. Results Discounting costs and QALYs at 3.5% per annum, avelumab was associated with ICERs of £35,274 (TE)/£39,178 (TN) per QALY gained. Probabilistic sensitivity analysis results demonstrated that avelumab was associated with an 88.3% (TE)/69.3% (TN) probability of being cost effective at a willingness-to-pay threshold for end-of-life treatments of £50,000 per QALY gained. Results were most sensitive to alternative survival extrapolations and dosing assumptions. Conclusions The analysis results suggest that avelumab is likely to be a cost-effective treatment option for UK mMCC patients. The results for TN patients are subject to some uncertainty, and a confirmatory analysis will be conducted with more mature data.

Suggested Citation

  • Ash Bullement & Paul Nathan & Anna Willis & Amerah Amin & Cameron Lilley & Ceilidh Stapelkamp & Anthony Hatswell & Chris Pescott & Murtuza Bharmal, 2019. "Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma," PharmacoEconomics - Open, Springer, vol. 3(3), pages 377-390, September.
  • Handle: RePEc:spr:pharmo:v:3:y:2019:i:3:d:10.1007_s41669-018-0115-y
    DOI: 10.1007/s41669-018-0115-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-018-0115-y
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-018-0115-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.
    2. Graeme Ball & Feng Xie & Jean-Eric Tarride, 2018. "Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada," PharmacoEconomics - Open, Springer, vol. 2(1), pages 19-29, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Zhaklin Stoykova-Valcheva, 2020. "Orphan Drugs of Personalized Medicine in Bulgaria and Their Cost-Effectiveness," Izvestia Journal of the Union of Scientists - Varna. Economic Sciences Series, Union of Scientists - Varna, Economic Sciences Section, vol. 9(3), pages 52-62, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind, 2017. "Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial," PharmacoEconomics - Open, Springer, vol. 1(3), pages 175-184, September.
    2. Micah Rose & Stephen Rice & Dawn Craig, 2018. "Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals," PharmacoEconomics - Open, Springer, vol. 2(2), pages 97-107, June.
    3. Olsen, Jan Abel & Lindberg, Marie Hella & Lamu, Admassu Nadew, 2020. "Health and wellbeing in Norway: Population norms and the social gradient," Social Science & Medicine, Elsevier, vol. 259(C).
    4. Billingsley Kaambwa & Julie Ratcliffe, 2018. "Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People’s Quality of Life Brief Questionnaire (OPQoL-Brief) Scores," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(1), pages 39-54, February.
    5. Aureliano Paolo Finch & John Brazier & Clara Mukuria, 2021. "Selecting Bolt-on Dimensions for the EQ-5D: Testing the Impact of Hearing, Sleep, Cognition, Energy, and Relationships on Preferences Using Pairwise Choices," Medical Decision Making, , vol. 41(1), pages 89-99, January.
    6. John Brazier & Roberta Ara & Donna Rowen & Helene Chevrou-Severac, 2017. "A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models," PharmacoEconomics, Springer, vol. 35(1), pages 21-31, December.
    7. Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson, 2017. "Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)," PharmacoEconomics, Springer, vol. 35(1), pages 111-124, January.
    8. Gutacker, Nils & Siciliani, Luigi & Cookson, Richard, 2016. "Waiting time prioritisation: Evidence from England," Social Science & Medicine, Elsevier, vol. 159(C), pages 140-151.
    9. Richard Cookson & Owen Cotton-Barrett & Matthew Adler & Miqdad Asaria & Toby Ord, 2016. "Years of good life based on income and health: Re-engineering cost-benefit analysis to examine policy impacts on wellbeing and distributive justice," Working Papers 132cherp, Centre for Health Economics, University of York.
    10. Olofsson, Sara & Gerdtham , Ulf-G & Hultkrantz , Lars & Persson , Ulf, 2016. "Chained Approach vs Contingent Valuation for Estimating the Value of Risk Reduction," Working Papers 2016:34, Lund University, Department of Economics.
    11. Louise Longworth & Donna Fountain & Jeshika Singh & Ismail Azzabi & Glynn Owen & Ulf Lundstam & Shaji Sebastian, 2019. "Elicitation of Health-Related Utility in Perianal Fistula in Crohn’s Disease," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 12(3), pages 339-348, June.
    12. Yan Feng & Nancy J. Devlin & Koonal K. Shah & Brendan Mulhern & Ben van Hout, 2018. "New methods for modelling EQ‐5D‐5L value sets: An application to English data," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 23-38, January.
    13. Wijnen, Ben F.M. & Mosweu, Iris & Majoie, Marian H.J.M. & Ridsdale, Leone & de Kinderen, Reina J.A. & Evers, Silvia M.A.A. & McCrone, Paul, 2018. "A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy," LSE Research Online Documents on Economics 106170, London School of Economics and Political Science, LSE Library.
    14. Mathieu F. Janssen & Gouke J. Bonsel & Nan Luo, 2018. "Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries," PharmacoEconomics, Springer, vol. 36(6), pages 675-697, June.
    15. Mihir Gandhi & Marcus Ang & Kelvin Teo & Chee Wai Wong & Yvonne Chung-Hsi Wei & Rachel Lee-Yin Tan & Mathieu F. Janssen & Nan Luo, 2020. "A vision ‘bolt-on’ increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 501-511, June.
    16. Maxwell Ogochukwu Adibe & Chibueze Anosike & Sunday Odunke Nduka & Abdulmuminu Isah, 2018. "Evaluation of Health Status of Type 2 Diabetes Outpatients Receiving Care in a Tertiary Hospital in Nigeria," PharmacoEconomics - Open, Springer, vol. 2(3), pages 337-345, September.
    17. Kristina Ludwig & J.-Matthias Graf von der Schulenburg & Wolfgang Greiner, 2018. "German Value Set for the EQ-5D-5L," PharmacoEconomics, Springer, vol. 36(6), pages 663-674, June.
    18. Héctor Pifarré i Arolas & Christian Dudel, 2019. "An Ordinal Measure of Population Health," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 143(3), pages 1219-1243, June.
    19. Asrul Akmal Shafie & Annushiah Vasan Thakumar & Ching Jou Lim & Nan Luo & Kim Rand-Hendriksen & Faridah Aryani Md Yusof, 2019. "EQ-5D-5L Valuation for the Malaysian Population," PharmacoEconomics, Springer, vol. 37(5), pages 715-725, May.
    20. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:3:y:2019:i:3:d:10.1007_s41669-018-0115-y. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: . General contact details of provider: http://www.springer.com .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.